and IPA of both the PCPT and PBCG risk tools were improved by including Prompt-PGS for both the PCPT and PBCG populations (Table 1). Observed versus expected plots (Figure 1) revealed superior calibration of inclusion of the Prompt-PGS score compared to either risk tool alone in both the PCPT and REDUCE populations, particularly on the lower end of risk. CONCLUSIONS: A germline-genetic risk stratification tool, Prompt e PGS, improves the performance of both the PCPT and PBCG risk tools in two large populations, particularly at the lower end of risk. It may be a useful tool for safely decreasing unnecessary prostate biopsies.